- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07629830
Post Exacerbation Asthma Clinic Telecare Intervention to Reduce Recurrent Exacerbations (PACT)
A Remote Clinic Intervention Following Hospital Discharge for Asthma Exacerbation to Reduce Recurrent Exacerbations
Asthma exacerbations leading to emergency department visits or hospitalization are associated with a high risk of recurrent exacerbations, poor disease control, and increased healthcare utilization in the months following discharge. Early specialist follow-up during this vulnerable transition period remains limited, and many patients do not receive optimized long-term asthma management. The purpose of this study is to evaluate whether a structured remote asthma clinic intervention initiated shortly after hospital discharge can reduce recurrent exacerbations and improve asthma-related outcomes compared to standard community care.
This prospective randomized study will enroll 220 adult patients (18-75 years) presenting to the emergency department at Tel Aviv Sourasky Medical Center with an asthma exacerbation. Participants will be randomly assigned to one of two groups:
- Intervention group - will undergo two structured remote pulmonology follow-up visits via secure video consultation within 7-21 days and 5 months after discharge, including treatment optimization, inhaler technique assessment, and self-management education.
- Control group - will continue standard community care without additional intervention.
All participants will complete scheduled follow-up assessments over 12 months, including evaluation of exacerbations, asthma control, healthcare utilization, and medication use.
연구 개요
상세 설명
Data collection:
Participants will be followed for 12 months after enrollment. In the intervention group, remote clinic visits will be conducted 7-21 days after discharge and again 5 months after enrollment. In addition, follow-up phone calls will be conducted at 3 months, 9 months, and 12 months after enrollment. The control group will undergo follow-up phone calls at the same assessment time points, without remote clinic intervention.
Data collected will include recurrent exacerbations, systemic corticosteroid use, emergency department visits, hospitalizations, medication changes, rescue inhaler use, and asthma symptom burden assessed using the Asthma Control Test (ACT).
Participants will be randomized to their respective intervention groups using a secure system of sequentially numbered, opaque, sealed envelopes (SNOSE) containing the treatment assignments. To maintain strict allocation concealment and minimize selection bias, the entire randomization process will be managed exclusively by an independent study coordinator. The principal investigators and clinical research team members directly involved in participant enrollment, care, and data collection will have no involvement in the generation, maintenance, or opening of the assignment envelopes. The independent coordinator will open the designated envelope only after a participant has successfully completed the baseline assessment and met all eligibility criteria.
Sample Size Calculation:
Based on preliminary data, the average exacerbation rate during the first 3 months is expected to be 0.25 exacerbations per patient in the control group and 0.10 in the intervention group. To detect this difference with 80% power and a significance level of 0.05, 100 participants are required in each group. Assuming a 10% loss to follow up, the planned sample size is 220 participants (110 participants per group).
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Amir Bar-Shai
- 전화번호: +972-507265248
- 이메일: amirbs@tlvmc.gov.il
연구 장소
-
-
-
Tel Aviv, 이스라엘
- Tel-Aviv Sourasky Medical Center, Tel Aviv
-
연락하다:
- Amir Bar-Shai, MD
- 전화번호: +972-507265248
- 이메일: amirbs@tlvmc.gov.il
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Presentation to the emergency department with an asthma exacerbation.
- Ability to complete telephone follow-up and access to a personal e-mail account.
- Agreement to participate in the study.
- Written or verbal informed consent according to study group assignment.
Exclusion Criteria:
- Uncontrolled cardiac disease.
- Any other uncontrolled medical condition.
- Inability to complete telephone follow-up.
- Pregnancy.
- Patients lacking decision-making capacity.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Control
Participants in the control group will continue standard community-based medical care following discharge from the emergency department or hospitalization for asthma exacerbation, without additional remote pulmonology intervention.
Follow-up assessments will be conducted by the research coordinator at predefined time points for study outcome evaluation only.
|
|
|
실험적: Remote Flare-Up Clinic
Participants in the intervention group will undergo structured remote pulmonology follow-up through secure video consultations conducted 7-21 days and 5 months after discharge following an asthma exacerbation.
The remote visits will include assessment of asthma control and exacerbation history, inhaler technique evaluation, treatment optimization according to current guidelines, and asthma self-management education.
Visit summaries and treatment recommendations will be documented in the electronic medical record and provided to the participant.
Additional follow-up phone assessments will be conducted by the research coordinator at predefined time points for study outcome evaluation.
|
Participants assigned to the intervention group will undergo two structured remote pulmonology visits via secure video consultation, conducted 7-21 days and 5 months after discharge following an asthma exacerbation.
The intervention will include assessment of asthma control and exacerbation history, inhaler technique evaluation, treatment optimization, and asthma self-management education according to current guidelines.
Additional follow-up phone assessments will be conducted at 3, 9, and 12 months for study outcome evaluation only.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Asthma Exacerbations Rate
기간: From enrollment to 3 months
|
The primary outcome will be the rate of severe asthma exacerbations, assessed as the total number of severe asthma exacerbations following enrollment divided by the number of participants in each study group.
The primary analysis will be performed according to the intention-to-treat principle.
severe asthma exacerbations defined as worsening asthma requiring treatment with systemic glucocorticoids for at least 3 days or worsening symptoms leading to an emergency department visit or hospitalization.
|
From enrollment to 3 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Hospital Arrival due to asthma exacerbations
기간: From enrollment to 3 months
|
The rate of asthma exacerbations leading to hospital arrival between the intervention and control.
|
From enrollment to 3 months
|
|
Change in Asthma Control Test (ACT) score
기간: From enrollment to 3 months
|
Change in asthma control score from baseline to 3 months between the intervention and control. Values range 5-25, with higher scores indicating better control. |
From enrollment to 3 months
|
|
Adherent to Treatment Guidelines
기간: From enrollment to 3 months
|
Treatment adhere to the Global Initiative for Asthma (GINA) guidelines based on disease severity, in the intervention vs. the control.
This will be defined as the percentage of patients taking the GINA-recommended inhaled corticosteroid dose, as self-reported in the 3-months follow-up.
|
From enrollment to 3 months
|
|
Percentage of ≥1 asthma exacerbations
기간: From enrollment to 3 months
|
The percentage of patients in each study groups that had ≥1 asthma exacerbations.
|
From enrollment to 3 months
|
|
Asthma Exacerbations Rate - extended follow-up
기간: From enrollment to 12 months
|
The primary outcome will be the rate of severe asthma exacerbations, assessed as the total number of severe asthma exacerbations following enrollment divided by the number of participants in each study group.
The primary analysis will be performed according to the intention-to-treat principle.
severe asthma exacerbations defined as worsening asthma requiring treatment with systemic glucocorticoids for at least 3 days or worsening symptoms leading to an emergency department visit or hospitalization.
|
From enrollment to 12 months
|
|
Hospital Arrival due to asthma exacerbations - extended follow-up
기간: From enrollment to 12 months
|
The rate of asthma exacerbations leading to hospital arrival between the intervention and control.
|
From enrollment to 12 months
|
|
Change in Asthma Control Test (ACT) score - extended follow-up
기간: From enrollment to 12 months
|
Change in asthma control score from baseline to 12 months between the intervention and control. Values range 5-25, with higher scores indicating better control. |
From enrollment to 12 months
|
|
Adherent to Treatment Guidelines - extended follow-up
기간: From enrollment to 12 months
|
Treatment adhere to the Global Initiative for Asthma (GINA) guidelines based on disease severity, in the intervention vs. the control.
This will be defined as the percentage of patients taking the GINA-recommended inhaled corticosteroid dose, as self-reported in the 12-months follow-up.
|
From enrollment to 12 months
|
|
Exacerbation Frequency
기간: From 12 months prior to enrollment through 12 months following enrollment.
|
Change in exacerbation frequency during the first year following enrollment compared to the year prior to study enrollment, defined as the percentage change in the rate of severe asthma exacerbations before and after the intervention.
|
From 12 months prior to enrollment through 12 months following enrollment.
|
|
Percentage of ≥1 asthma exacerbations - extended follow-up
기간: From enrollment to 12 months
|
The percentage of patients in each study groups that had ≥1 asthma exacerbations.
|
From enrollment to 12 months
|
공동 작업자 및 조사자
간행물 및 유용한 링크
유용한 링크
- 2023 GINA Main Report. Global Initiative for Asthma - GINA
- High Prevalence of Severe Asthma in a Large Random Population Study.
- The Barriers to Accessing Primary Care Resulting in Hospital Presentation for Exacerbation of Asthma or Chronic Obstructive Pulmonary Disease in a Large Teaching Hospital in London.
- Asthma Patients' and Physicians' Perspectives on the Burden and Management of Asthma.
- Asthmatic Patients' Poor Awareness of Inadequate Disease Control: A Pharmacy-Based Survey.
- Prevalence, Risk Factors, and Management of Asthma in China: A National Cross-Sectional Study.
- Positive Change in Asthma Control Using Therapeutic Patient Education in Severe Uncontrolled Asthma: A One-Year Prospective Study.
- Economic Evidence for US Asthma Self-Management Education and Home-Based Interventions.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 0034-26-TLV
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .